Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
PC

NASDAQ · PCSA

Processa Pharmaceuticals, Inc.

Healthcare · Biotechnology

$2.08

Up+$0.23 (+12.43%)

Updated Sep 13, 2026, 5:19 PM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
15.65M
P/E ratio
-1.01
Dividend yield
0.00%
52-week range
$1.67 – $3.45
Volume
39.35K
Avg. volume
9.87M

Price performance

PCSA price history

1M range · 19 trading sessions · Daily adjusted prices

PCSA closed at $2.08 after 19 trading sessions, down 2.35% for the selected period.

Last close
$2.08
Period change
-2.35%
Period low
$1.85
Period high
$2.18
Daily close
View OHLC price history
PCSA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$1.90$2.12$1.90$2.0839.35K
Sep 10, 2026$1.99$2.03$1.82$1.85102.28K
Sep 9, 2026$2.08$2.11$1.98$1.9925.47K
Sep 8, 2026$2.15$2.165$2.05$2.1635.84K
Sep 4, 2026$2.02$2.0825$2.01$2.0612.34K
Sep 3, 2026$2.09$2.10$2.05$2.0510.3K
Sep 2, 2026$2.05$2.18$2.05$2.1012.72K
Sep 1, 2026$2.04$2.125$2.02$2.0514.53K
Aug 31, 2026$2.08$2.11$2.02$2.0515.7K
Aug 28, 2026$2.08$2.14$2.02$2.069.59K
Aug 27, 2026$2.07$2.20$2.07$2.1115.87K
Aug 26, 2026$2.18$2.22$2.12$2.1321.97K
Aug 25, 2026$2.17$2.28$2.15$2.1856.22K
Aug 24, 2026$2.11$2.18$2.04$2.1730.51K
Aug 21, 2026$2.21$2.22$2.00$2.0875.97K
Aug 20, 2026$2.14$2.1999$2.11$2.14527.54K
Aug 19, 2026$2.18$2.18$2.11$2.1525.07K
Aug 18, 2026$2.13$2.1536$2.04$2.1051.88K
Aug 17, 2026$2.43$2.43$2.12$2.1361.31K

Latest PCSA news

The latest Smart Investors Daily articles mentioning PCSA.

Stock researchCompany · Overview

PCSA research

Overview

Company profile and research snapshot.

Company profile

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.00
Implied upside
—
Analysts
8
PCSA recent ratings
DateFirmRatingTarget
Sep 2, 2025HC Wainwright & Co.Buy—
Jun 30, 2025HC Wainwright & Co.Buy—
Dec 5, 2024HC Wainwright & Co.Buy—
Oct 3, 2024HC Wainwright & Co.Buy—
Aug 20, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

globenewswire.com · Nov 5, 2025

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 (499) in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, has been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9, 2025, in Houston, Texas.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By